Weight Loss Jabs Could Save Heart Attack Survivors

Weight loss medications, including Ozempic and Wegovy, may offer a significant benefit in preventing severe complications after a heart attack. A recent study indicates these GLP-1 drugs can mitigate tissue damage and help reopen small blood vessels in the heart that often remain narrowed even after emergency treatment.

Researchers found that these drugs work by affecting pericytes, cells that constrict blood vessels during a heart attack. By activating potassium channels, GLP-1 drugs relax these cells, improving blood flow and reducing the risk of 'no-reflow,' a condition where blood cannot reach parts of the heart muscle.

The findings raise the possibility of paramedics administering these GLP-1 drugs at the scene of a heart attack, potentially boosting survival rates. Experts suggest that these existing drugs could be repurposed to address the 'no-reflow' risk in heart attack patients, offering a novel, life-saving solution.

While previous studies have highlighted the cardiovascular benefits of GLP-1 medicines beyond weight loss, this research offers a potential explanation for how they improve blood flow through the heart's microvessels. Further clinical trials are needed to confirm these findings in humans.